

# Scott A Waldman

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/774846/scott-a-waldman-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

275 papers	8,689 citations	51 h-index	79 g-index
320 ext. papers	9,636 ext. citations	5.2 avg, IF	5.78 L-index

#	Paper	IF	Citations
275	T-Cell Responses to Immunodominant <i>Listeria</i> Epitopes Limit Vaccine-Directed Responses to the Colorectal Cancer Antigen, Guanylyl Cyclase C.. <i>Frontiers in Immunology</i> , <b>2022</b> , 13, 855759	8.4	0
274	Real-World Treatment Strategies to Improve Outcomes in Patients With Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation.. <i>American Journal of Gastroenterology</i> , <b>2022</b> , 117, S21-S26	0.7	1
273	Mechanisms of Action of Current Pharmacologic Options for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation.. <i>American Journal of Gastroenterology</i> , <b>2022</b> , 117, S6-S13	0.7	1
272	GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , <b>2021</b> , 6, 117-129	1.6	3
271	Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers. <i>Cancer Biology and Therapy</i> , <b>2021</b> , 1-10	4.6	0
270	Stem cells as therapeutic targets in colorectal cancer. <i>Personalized Medicine</i> , <b>2021</b> , 18, 171-183	2.2	0
269	Review article: diagnosis, management and patient perspectives of the spectrum of constipation disorders. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 1250-1267	6.1	9
268	Guanylyl cyclase 2C (GUCY2C) in gastrointestinal cancers: recent innovations and therapeutic potential. <i>Expert Opinion on Therapeutic Targets</i> , <b>2021</b> , 25, 335-346	6.4	0
267	The shifting paradigm of colorectal cancer treatment: a look into emerging cancer stem cell-directed therapeutics to lead the charge toward complete remission. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 1335-1345	5.4	1
266	Emerging targets for the diagnosis of Parkinson's disease: examination of systemic biomarkers. <i>Biomarkers in Medicine</i> , <b>2021</b> , 15, 597-608	2.3	
265	From leptin to lasers: the past and present of mouse models of obesity. <i>Expert Opinion on Drug Discovery</i> , <b>2021</b> , 16, 777-790	6.2	
264	Guanylyl cyclase C as a biomarker for immunotherapies for the treatment of gastrointestinal malignancies. <i>Biomarkers in Medicine</i> , <b>2021</b> , 15, 201-217	2.3	0
263	Silencing the intestinal GUCY2C tumor suppressor axis requires loss of heterozygosity. <i>Cancer Biology and Therapy</i> , <b>2020</b> , 21, 799-805	4.6	5
262	APC-Eatenin-TCF signaling silences the intestinal guanylin-GUCY2C tumor suppressor axis. <i>Cancer Biology and Therapy</i> , <b>2020</b> , 21, 441-451	4.6	5
261	Cardiopietic stem cell therapy in ischaemic heart failure: long-term clinical outcomes. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 3345	3.7	12
260	An update on guanylyl cyclase C in the diagnosis, chemoprevention, and treatment of colorectal cancer. <i>Expert Review of Clinical Pharmacology</i> , <b>2020</b> , 13, 1125-1137	3.8	2
259	Chimeric Ad5.F35 vector evades anti-adenovirus serotype 5 neutralization opposing GUCY2C-targeted antitumor immunity <b>2020</b> , 8,		9

258	Two distinct GUCY2C circuits with PMV (hypothalamic) and SN/VTA (midbrain) origin. <i>Brain Structure and Function</i> , <b>2019</b> , 224, 2983-2999	4	10
257	Silencing the GUCA2A-GUCY2C tumor suppressor axis in CIN, serrated, and MSI colorectal neoplasia. <i>Human Pathology</i> , <b>2019</b> , 87, 103-114	3.7	9
256	Therapeutic targeting of gastrointestinal cancer stem cells. <i>Regenerative Medicine</i> , <b>2019</b> , 14, 331-343	2.5	5
255	Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients <b>2019</b> , 7, 104		23
254	Biomarker targeting of colorectal cancer stem cells. <i>Biomarkers in Medicine</i> , <b>2019</b> , 13, 891-894	2.3	2
253	NHERF3 is necessary for heat-stable enterotoxin-induced inhibition of NHE3: differences in signaling in mouse small intestine and Caco-2 cells. <i>American Journal of Physiology - Cell Physiology</i> , <b>2019</b> , 317, C737-C748	5.4	6
252	Guanylate cyclase C (GUCY2C) as a preventative and therapeutic target in colorectal cancers (CRCs) arising through divergent genomic pathways.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 595-595	2.2	
251	Blunted Evoked Prouroguanylin Endocrine Secretion in Chronic Constipation. <i>Clinical and Translational Gastroenterology</i> , <b>2019</b> , 10, e00016	4.2	3
250	TCR Retrogenic Mice as a Model To Map Self-Tolerance Mechanisms to the Cancer Mucosa Antigen GUCY2C. <i>Journal of Immunology</i> , <b>2019</b> , 202, 1301-1310	5.3	5
249	Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases. <i>Cancer Immunology Research</i> , <b>2018</b> , 6, 509-516	12.5	53
248	First-in-Human Use of a Retention-Enhanced Catheter for Endomyocardial Cell Delivery. <i>JACC: Cardiovascular Interventions</i> , <b>2018</b> , 11, 412-414	5	3
247	Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders. <i>Gut</i> , <b>2018</b> , 67, 1543-1552	19.2	47
246	Modeling qRT-PCR dynamics with application to cancer biomarker quantification. <i>Statistical Methods in Medical Research</i> , <b>2018</b> , 27, 2581-2595	2.3	4
245	The Guanylate Cyclase C-cGMP Signaling Axis Opposes Intestinal Epithelial Injury and Neoplasia. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 299	5.3	22
244	Myeloid-specific deletion of Zfp36 protects against insulin resistance and fatty liver in diet-induced obese mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2018</b> , 315, E676-E693	6	5
243	Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 549-557	3.8	18
242	Bioactivity of Oral Linaclotide in Human Colorectum for Cancer Chemoprevention. <i>Cancer Prevention Research</i> , <b>2017</b> , 10, 345-354	3.2	19
241	Prime-Boost Immunization Eliminates Metastatic Colorectal Cancer by Producing High-Avidity Effector CD8 T Cells. <i>Journal of Immunology</i> , <b>2017</b> , 198, 3507-3514	5.3	25

240	GUICY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome. <i>Cancer Research</i> , <b>2017</b> , 77, 5095-5106	8
239	Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis. <i>Annals of Oncology</i> , <b>2017</b> , 28, 2135-2141	10.3 61
238	ST-Producing E. coli Oppose Carcinogen-Induced Colorectal Tumorigenesis in Mice. <i>Toxins</i> , <b>2017</b> , 9,	4.9 11
237	GUICY2C maintains intestinal LGR5 stem cells by opposing ER stress. <i>Oncotarget</i> , <b>2017</b> , 8, 102923-102933	3.3 6
236	Cardiopietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. <i>European Heart Journal</i> , <b>2017</b> , 38, 648-660	9.5 113
235	GUICY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity. <i>Oncolmmunology</i> , <b>2016</b> , 5, e1227897	7.2 40
234	Association of Inflammation prior to Kidney Transplantation with Post-Transplant Diabetes Mellitus. <i>CardioRenal Medicine</i> , <b>2016</b> , 6, 289-300	2.8 6
233	Guanylyl Cyclase C Hormone Axis at the Intersection of Obesity and Colorectal Cancer. <i>Molecular Pharmacology</i> , <b>2016</b> , 90, 199-204	4.3 9
232	GUICY2C ligand replacement to prevent colorectal cancer. <i>Cancer Biology and Therapy</i> , <b>2016</b> , 17, 713-8	4.6 11
231	Obesity-Induced Colorectal Cancer Is Driven by Caloric Silencing of the Guanylin-GUICY2C Paracrine Signaling Axis. <i>Cancer Research</i> , <b>2016</b> , 76, 339-46	10.1 51
230	Guanylyl cyclase C signaling axis and colon cancer prevention. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 8070-7	5.6 28
229	A survey of physician receptivity to molecular diagnostic testing and readiness to act on results for early-stage colon cancer patients. <i>BMC Cancer</i> , <b>2016</b> , 16, 766	4.8 3
228	Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope. <i>Human Gene Therapy Methods</i> , <b>2016</b> , 27, 238-250	4.9 14
227	Calorie-induced ER stress suppresses uroguanylin satiety signaling in diet-induced obesity. <i>Nutrition and Diabetes</i> , <b>2016</b> , 6, e211	4.7 22
226	Intestinal Enteroids Model Guanylate Cyclase C-Dependent Secretion Induced by Heat-Stable Enterotoxins. <i>Infection and Immunity</i> , <b>2016</b> , 84, 3083-91	3.7 21
225	CD19-Targeted Nanodelivery of Doxorubicin Enhances Therapeutic Efficacy in B-Cell Acute Lymphoblastic Leukemia. <i>Molecular Pharmaceutics</i> , <b>2015</b> , 12, 2101-11	5.6 28
224	Companion diagnostics at the intersection of personalized medicine and healthcare delivery. <i>Biomarkers in Medicine</i> , <b>2015</b> , 9, 1-3	2.3 9
223	Plp1 gene duplication inhibits airway responsiveness and induces lung inflammation. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2015</b> , 30, 22-31	3.5

222	A Phase I study of AD5-GUCY2C-PADRE in stage I and II colon cancer patients <b>2015</b> , 3,		11
221	Guanylyl Cyclase C as a Biomarker. <i>Biomarkers in Disease</i> , <b>2015</b> , 363-381		
220	Calorie-induced ER Stress Silences the Guanylin-GUCY2C Paracrine Axis Underlying Colorectal Cancer in Obesity. <i>FASEB Journal</i> , <b>2015</b> , 29, LB542	0.9	
219	Policies to aid the adoption of personalized medicine. <i>Nature Reviews Drug Discovery</i> , <b>2014</b> , 13, 159-60	64.1	4
218	Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy. <i>European Journal of Immunology</i> , <b>2014</b> , 44, 1956-66	6.1	30
217	The orl rat is more responsive to methacholine challenge than wild type. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2014</b> , 29, 199-208	3.5	3
216	Tumor radiation therapy creates therapeutic vaccine responses to the colorectal cancer antigen GUCY2C. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 88, 1188-95	4	23
215	Antiobesity pharmacotherapy: new drugs and emerging targets. <i>Clinical Pharmacology and Therapeutics</i> , <b>2014</b> , 95, 53-66	6.1	123
214	A novel CDX2 isoform regulates alternative splicing. <i>PLoS ONE</i> , <b>2014</b> , 9, e104293	3.7	3
213	Gut-Brain Endocrine Axes in Weight Regulation and Obesity Pharmacotherapy. <i>Journal of Clinical Medicine</i> , <b>2014</b> , 3, 763-94	5.1	8
212	Adiponectin receptor and adiponectin signaling in human tissue among patients with end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , <b>2014</b> , 29, 2268-77	4.3	35
211	The paracrine hormone for the GUCY2C tumor suppressor, guanylin, is universally lost in colorectal cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2014</b> , 23, 2328-37	4	35
210	GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer. <i>Oncotarget</i> , <b>2014</b> , 5, 9460-71	3.3	21
209	Guanylyl Cyclase C as Biomarker <b>2014</b> , 1-16		
208	Dexamethasone-loaded block copolymer nanoparticles induce leukemia cell death and enhance therapeutic efficacy: a novel application in pediatric nanomedicine. <i>Molecular Pharmaceutics</i> , <b>2013</b> , 10, 2199-210	5.6	50
207	GUCY2C: at the intersection of obesity and cancer. <i>Trends in Endocrinology and Metabolism</i> , <b>2013</b> , 24, 165-73	8.8	14
206	Genetics and genomics for the prevention and treatment of cardiovascular disease: update: a scientific statement from the American Heart Association. <i>Circulation</i> , <b>2013</b> , 128, 2813-51	16.7	76
205	Obesity pharmacotherapy: what is next?. <i>Molecular Aspects of Medicine</i> , <b>2013</b> , 34, 71-83	16.7	45

204	Reply: The C-CURE Randomized Clinical Trial (Cardiopoietic stem Cell therapy in heart failURE). <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 2454-2456	15.1	13
203	Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 61, 2329-38	15.1	360
202	Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis. <i>Expert Review of Clinical Pharmacology</i> , <b>2013</b> , 6, 557-64	3.8	6
201	Translational medicine individualizes healthcare discovery, development and delivery. Foreword. <i>Biomarkers in Medicine</i> , <b>2013</b> , 7, 1-3	2.3	6
200	New advances in models and strategies for developing anti-obesity drugs. <i>Expert Opinion on Drug Discovery</i> , <b>2013</b> , 8, 655-71	6.2	18
199	Immunotherapeutic strategies to target prognostic and predictive markers of cancer. <i>Biomarkers in Medicine</i> , <b>2013</b> , 7, 23-35	2.3	7
198	Intestinal GUCY2C prevents TGF- $\beta$ secretion coordinating desmoplasia and hyperproliferation in colorectal cancer. <i>Cancer Research</i> , <b>2013</b> , 73, 6654-66	10.1	16
197	Guanylyl cyclase C as a biomarker in colorectal cancer. <i>Biomarkers in Medicine</i> , <b>2013</b> , 7, 159-67	2.3	13
196	The adipose tissue production of adiponectin is increased in end-stage renal disease. <i>Kidney International</i> , <b>2013</b> , 83, 487-94	9.9	44
195	Systems approaches evolve clinical pharmacology. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2013</b> , 2, e68	4.5	4
194	Molecular staging of node negative patients with colorectal cancer. <i>Journal of Cancer</i> , <b>2013</b> , 4, 193-9	4.5	15
193	Evidence-based Guidelines for Precision Risk Stratification-Based Screening (PRSBS) for Colorectal Cancer: Lessons learned from the US Armed Forces: Consensus and Future Directions. <i>Journal of Cancer</i> , <b>2013</b> , 4, 172-92	4.5	11
192	Mechanisms of Weight Regain following Weight Loss. <i>ISRN Obesity</i> , <b>2013</b> , 2013, 210524		56
191	Colorectal cancer immunotherapy. <i>Discovery Medicine</i> , <b>2013</b> , 15, 301-8	2.5	46
190	Advances in cancer immunotherapy. <i>Discovery Medicine</i> , <b>2013</b> , 15, 120-5	2.5	8
189	The value proposition of molecular medicine. <i>Clinical and Translational Science</i> , <b>2012</b> , 5, 108-10	4.9	2
188	GUCY2C opposes systemic genotoxic tumorigenesis by regulating AKT-dependent intestinal barrier integrity. <i>PLoS ONE</i> , <b>2012</b> , 7, e31686	3.7	58
187	Molecular staging individualizing cancer management. <i>Journal of Surgical Oncology</i> , <b>2012</b> , 105, 468-74	2.8	17

186	Analytic lymph node number establishes staging accuracy by occult tumor burden in colorectal cancer. <i>Journal of Surgical Oncology</i> , <b>2012</b> , 106, 24-30	2.8	9
185	Phosphorylation of vasodilator-stimulated phosphoprotein Ser239 suppresses filopodia and invadopodia in colon cancer. <i>International Journal of Cancer</i> , <b>2012</b> , 130, 2539-48	7.5	31
184	Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes. <i>Cancer</i> , <b>2012</b> , 118, 2532-40	6.4	12
183	Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer mucosa antigen GUCY2C. <i>Cancer Immunology, Immunotherapy</i> , <b>2012</b> , 61, 713-23	7.4	20
182	GUCY2C molecular staging personalizes colorectal cancer patient management. <i>Biomarkers in Medicine</i> , <b>2012</b> , 6, 339-48	2.3	3
181	Effect of a novel CDX2 splice variant on tumorigenicity in gastroesophageal junction adenocarcinoma xenografts.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e14619-e14619	2.2	
180	MicroRNA Signatures as Diagnostic and Therapeutic Targets. <i>Laboratory Medicine Online</i> , <b>2011</b> , 1, 1	0.2	
179	A conserved tissue-specific homeodomain-less isoform of MEIS1 is downregulated in colorectal cancer. <i>PLoS ONE</i> , <b>2011</b> , 6, e23665	3.7	22
178	Contrast-enhanced ultrasound imaging of sentinel lymph nodes after peritumoral administration of Sonazoid in a melanoma tumor animal model. <i>Journal of Ultrasound in Medicine</i> , <b>2011</b> , 30, 441-53	2.9	33
177	Clinical translational science 2020: disruptive innovation redefines the discovery-application enterprise. <i>Clinical and Translational Science</i> , <b>2011</b> , 4, 69-71	4.9	8
176	Bionic technologies transforming the science of healthcare delivery. <i>Clinical and Translational Science</i> , <b>2011</b> , 4, 84-6	4.9	2
175	Chronic diseases: the emerging pandemic. <i>Clinical and Translational Science</i> , <b>2011</b> , 4, 225-6	4.9	72
174	GUCY2C-targeted cancer immunotherapy: past, present and future. <i>Immunologic Research</i> , <b>2011</b> , 51, 161-9	4.3	8
173	Regulation of appetite to treat obesity. <i>Expert Review of Clinical Pharmacology</i> , <b>2011</b> , 4, 243-59	3.8	32
172	Occult tumor burden predicts disease recurrence in lymph node-negative colorectal cancer. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 3293-303	12.9	25
171	Patient-centric clinical pharmacology advances the path to personalized medicine. <i>Biomarkers in Medicine</i> , <b>2011</b> , 5, 697-700	2.3	9
170	A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. <i>Journal of Clinical Investigation</i> , <b>2011</b> , 121, 3578-88	15.9	105
169	Central and peripheral molecular targets for antiobesity pharmacotherapy. <i>Clinical Pharmacology and Therapeutics</i> , <b>2010</b> , 87, 652-62	6.1	37



168	Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2010</b> , 5, 765-783	4.1	3
167	Corruption of homeostatic mechanisms in the guanylyl cyclase C signaling pathway underlying colorectal tumorigenesis. <i>Cancer Biology and Therapy</i> , <b>2010</b> , 10, 211-8	4.6	9
166	Molecular staging estimates occult tumor burden in colorectal cancer. <i>Advances in Clinical Chemistry</i> , <b>2010</b> , 52, 19-39	5.8	3
165	Expression of the intestinal biomarkers Guanylyl cyclase C and CDX2 in poorly differentiated colorectal carcinomas. <i>Human Pathology</i> , <b>2010</b> , 41, 123-8	3.7	26
164	Molecular therapy drives patient-centric health care paradigms. <i>Clinical and Translational Science</i> , <b>2010</b> , 3, 170-1	4.9	6
163	Bacterial heat-stable enterotoxins: translation of pathogenic peptides into novel targeted diagnostics and therapeutics. <i>Toxins</i> , <b>2010</b> , 2, 2028-54	4.9	25
162	Selection of optimal reference genes for normalization in quantitative RT-PCR. <i>BMC Bioinformatics</i> , <b>2010</b> , 11, 253	3.6	63
161	Sizing up pharmacotherapy for obesity. <i>Clinical and Translational Science</i> , <b>2010</b> , 3, 123-5	4.9	2
160	Clinical and translational science: from bench-bedside to global village. <i>Clinical and Translational Science</i> , <b>2010</b> , 3, 254-7	4.9	51
159	Chemiluminescence-based detection of gastrointestinal malignancies. <i>Luminescence</i> , <b>2010</b> , 25, 463-5	2.5	4
158	GUCY2C reverse transcriptase PCR to stage pN0 colorectal cancer patients. <i>Expert Review of Molecular Diagnostics</i> , <b>2009</b> , 9, 777-85	3.8	11
157	Guanylyl cyclase C as a biomarker for targeted imaging and therapy of metastatic colorectal cancer. <i>Biomarkers in Medicine</i> , <b>2009</b> , 3, 33-45	2.3	7
156	Association of GUCY2C expression in lymph nodes with time to recurrence and disease-free survival in pN0 colorectal cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2009</b> , 301, 745-52	27.4	88
155	Clinical pharmacology: a paradigm for individualized medicine. <i>Biomarkers in Medicine</i> , <b>2009</b> , 3, 679-84	2.3	7
154	Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target. <i>Future Oncology</i> , <b>2009</b> , 5, 509-22	3.6	22
153	Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. <i>Cancer Research</i> , <b>2009</b> , 69, 3537-44	10.1	31
152	Guanylyl cyclase C prevents colon cancer metastasis by regulating tumor epithelial cell matrix metalloproteinase-9. <i>Cancer Research</i> , <b>2009</b> , 69, 3529-36	10.1	33
151	Molecular diagnostics. At the nexus of individualized medicine, health care delivery, and public policy. <i>Clinical and Translational Science</i> , <b>2009</b> , 2, 6-8	4.9	3



150	Translational medicine in the era of health care reform. <i>Clinical and Translational Science</i> , <b>2009</b> , 2, 96-7	4.9	7
149	Applications of microRNA in cancer: Exploring the advantages of miRNA. <i>Clinical and Translational Science</i> , <b>2009</b> , 2, 248-9	4.9	8
148	Bile acids initiate lineage-addicted gastroesophageal tumorigenesis by suppressing the EGF receptor-AKT axis. <i>Clinical and Translational Science</i> , <b>2009</b> , 2, 286-93	4.9	8
147	Experimental therapeutics: a paradigm for personalized medicine. <i>Clinical and Translational Science</i> , <b>2009</b> , 2, 436-8	4.9	8
146	Guanylyl cyclase C is a specific marker for differentiating primary and metastatic ovarian mucinous neoplasms. <i>Histopathology</i> , <b>2009</b> , 55, 182-8	7.3	2
145	A study of microRNAs in silico and in vivo: diagnostic and therapeutic applications in cancer. <i>FEBS Journal</i> , <b>2009</b> , 276, 2157-64	5.7	28
144	Transitioning biomarkers into the clinic. <i>Expert Review of Clinical Pharmacology</i> , <b>2009</b> , 2, 9-13	3.8	1
143	GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome?. <i>Drug News and Perspectives</i> , <b>2009</b> , 22, 313-8		20
142	CANCER MUCOSA ANTIGENS A NOVEL PARADIGM IN CANCER IMMUNOTHERAPEUTICS <b>2009</b> , 3, 14-16		1
141	PHARMACOTHERAPEUTIC CONTINUUM: ENGINEERING THE FUTURE OF INDIVIDUALIZED MEDICINE <b>2009</b> , 3-5		
140	The Novel Role of Guanylyl Cyclase C Signaling in Appetite Suppression and Body Weight Regulation. <i>FASEB Journal</i> , <b>2009</b> , 23, LB365	0.9	
139	Sex modulates intestinal transformation by the tumor-suppressor GCC. <i>Clinical and Translational Science</i> , <b>2008</b> , 1, 150	4.9	
138	Clinical and translational sciences: at the intersection of molecular and individualized medicine. <i>Clinical and Translational Science</i> , <b>2008</b> , 1, 6-8	4.9	6
137	Sex modulates intestinal transformation by the tumor-suppressor GCC. <i>Clinical and Translational Science</i> , <b>2008</b> , 1, 146-50	4.9	
136	Colorectal cancer is a paracrine deficiency syndrome amenable to oral hormone replacement therapy. <i>Clinical and Translational Science</i> , <b>2008</b> , 1, 163-7	4.9	20
135	The roadmap to personalized medicine. <i>Clinical and Translational Science</i> , <b>2008</b> , 1, 93	4.9	5
134	Cytokine adjuvation of therapeutic anti-tumor immunity targeted to cancer mucosa antigens. <i>Clinical and Translational Science</i> , <b>2008</b> , 1, 263-4	4.9	7
133	Aprepitant for the prevention of nausea and vomiting associated with chemotherapy and postoperative recovery. <i>Expert Review of Clinical Pharmacology</i> , <b>2008</b> , 1, 27-37	3.8	2

132	Bridging the therapeutic continuum of drug development, regulation and use. <i>Expert Review of Clinical Pharmacology</i> , <b>2008</b> , 1, 1-3	3.8	
131	Enterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cells. <i>Carcinogenesis</i> , <b>2008</b> , 29, 1601-7	4.6	23
130	Previstage GCC test for staging patients with colorectal cancer. <i>Expert Review of Molecular Diagnostics</i> , <b>2008</b> , 8, 571-8	3.8	8
129	Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. <i>Journal of the National Cancer Institute</i> , <b>2008</b> , 100, 950-61	9.7	43
128	Derivation and fluidity of acutely induced dysfunctional CD8+ T cells. <i>Journal of Immunology</i> , <b>2008</b> , 180, 5300-8	5.3	3
127	MicroRNA signatures as diagnostic and therapeutic targets. <i>Clinical Chemistry</i> , <b>2008</b> , 54, 943-4	5.5	42
126	STa peptide analogs for probing guanylyl cyclase C. <i>Biopolymers</i> , <b>2008</b> , 90, 713-23	2.2	7
125	H-ras inhibits RhoA/ROCK leading to a decrease in the basal tone in the internal anal sphincter. <i>Gastroenterology</i> , <b>2007</b> , 132, 1401-9	13.3	7
124	Guanylyl cyclase C suppresses intestinal tumorigenesis by restricting proliferation and maintaining genomic integrity. <i>Gastroenterology</i> , <b>2007</b> , 133, 599-607	13.3	102
123	Relative quantification based on logistic models for individual polymerase chain reactions. <i>Statistics in Medicine</i> , <b>2007</b> , 26, 5596-611	2.3	22
122	The paracrine hormone hypothesis of colorectal cancer. <i>Clinical Pharmacology and Therapeutics</i> , <b>2007</b> , 82, 441-7	6.1	49
121	Cancer mucosa antigens as a novel immunotherapeutic class of tumor-associated antigen. <i>Clinical Pharmacology and Therapeutics</i> , <b>2007</b> , 82, 734-9	6.1	27
120	Applications of nanoparticles to diagnostics and therapeutics in colorectal cancer. <i>Trends in Biotechnology</i> , <b>2007</b> , 25, 145-52	15.1	119
119	Mucosally restricted antigens as novel immunological targets for antitumor therapy. <i>Biomarkers in Medicine</i> , <b>2007</b> , 1, 187-202	2.3	10
118	Translating MicroRNA discovery into clinical biomarkers in cancer. <i>JAMA - Journal of the American Medical Association</i> , <b>2007</b> , 297, 1923-5	27.4	46
117	The pharmacokinetics of taurolidine metabolites in healthy volunteers. <i>Journal of Clinical Pharmacology</i> , <b>2007</b> , 47, 697-703	2.9	20
116	Homeostatic control of the crypt-villus axis by the bacterial enterotoxin receptor guanylyl cyclase C restricts the proliferating compartment in intestine. <i>American Journal of Pathology</i> , <b>2007</b> , 171, 1847-58	5.8	89
115	Where medicine, business, and public policy intersect. <i>Biotechnology Healthcare</i> , <b>2007</b> , 4, 33-42		7

114	Opportunities for near-infrared thermal ablation of colorectal metastases by guanylyl cyclase C-targeted gold nanoshells. <i>Future Oncology</i> , <b>2006</b> , 2, 705-16	3.6	16
113	A validated quantitative assay to detect occult micrometastases by reverse transcriptase-polymerase chain reaction of guanylyl cyclase C in patients with colorectal cancer. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 4545-52	12.9	70
112	Tumor epithelial cell matrix metalloproteinase 9 is a target for antimetastatic therapy in colorectal cancer. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 1876-82	12.9	54
111	Exisulind and guanylyl cyclase C induce distinct antineoplastic signaling mechanisms in human colon cancer cells. <i>Molecular Cancer Therapeutics</i> , <b>2006</b> , 5, 1190-6	6.1	12
110	Bile acids induce ectopic expression of intestinal guanylyl cyclase C Through nuclear factor-kappaB and Cdx2 in human esophageal cells. <i>Gastroenterology</i> , <b>2006</b> , 130, 1191-206	13.3	76
109	Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. <i>Journal of Clinical Pharmacology</i> , <b>2006</b> , 46, 291-300	2.9	69
108	Statistical algorithm for assuring similar efficiency in standards and samples for absolute quantification by real-time reverse transcription polymerase chain reaction. <i>Analytical Biochemistry</i> , <b>2006</b> , 348, 198-208	3.1	18
107	Tumor-targeting peptide-PNA-peptide chimeras for imaging overexpressed oncogene mRNAs. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , <b>2005</b> , 24, 1085-91	1.4	11
106	Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and adenocarcinoma of the gastrointestinal tract. <i>Human Pathology</i> , <b>2005</b> , 36, 170-9	3.7	96
105	Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. <i>Expert Review of Molecular Diagnostics</i> , <b>2005</b> , 5, 701-13	3.8	57
104	The putative tumor suppressor Cdx2 is overexpressed by human colorectal adenocarcinomas. <i>Clinical Cancer Research</i> , <b>2005</b> , 11, 8549-56	12.9	69
103	Interruption of homologous desensitization in cyclic guanosine 3'Smonophosphate signaling restores colon cancer cytostasis by bacterial enterotoxins. <i>Cancer Research</i> , <b>2005</b> , 65, 11129-35	10.1	30
102	Proliferative signaling by store-operated calcium channels opposes colon cancer cell cytostasis induced by bacterial enterotoxins. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2005</b> , 314, 1013-22	4.7	26
101	Potential for interactions between caspofungin and nelfinavir or rifampin. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2004</b> , 48, 4306-14	5.9	80
100	Reciprocal regulation and integration of signaling by intracellular calcium and cyclic GMP. <i>Vitamins and Hormones</i> , <b>2004</b> , 69, 69-94	2.5	1
99	Guanylyl cyclase is an ATP sensor coupling nitric oxide signaling to cell metabolism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 37-42	11.5	82
98	Markers of cell cycle-mediated drug resistance and prognosis of patients receiving preoperative combined modality therapy for rectal cancer. <i>Annals of Surgical Oncology</i> , <b>2004</b> , 11, 949-50	3.1	2
97	Comparative disposition of [14C]ertapenem, a novel carbapenem antibiotic, in rat, monkey and man. <i>Xenobiotica</i> , <b>2004</b> , 34, 379-89	2	18

96	Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study. <i>Clinical Pharmacokinetics</i> , <b>2004</b> , 43, 121-9	6.2	15
95	The pharmacokinetics of nebulized nanocrystal budesonide suspension in healthy volunteers. <i>Journal of Clinical Pharmacology</i> , <b>2004</b> , 44, 67-72	2.9	40
94	Indinavir and rifabutin drug interactions in healthy volunteers. <i>Journal of Clinical Pharmacology</i> , <b>2004</b> , 44, 305-13	2.9	23
93	Nitric oxide signaling: systems integration of oxygen balance in defense of cell integrity. <i>Current Opinion in Hematology</i> , <b>2004</b> , 11, 7-14	3.3	25
92	The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity. <i>Journal of Clinical Pharmacology</i> , <b>2004</b> , 44, 1125-31	2.9	15
91	Pathological staging and therapy of oesophageal and gastric cancer. <i>Expert Opinion on Pharmacotherapy</i> , <b>2003</b> , 4, 1083-96	4	4
90	Relationship of arachidonic acid concentration to cyclooxygenase-dependent human platelet aggregation. <i>Journal of Clinical Pharmacology</i> , <b>2003</b> , 43, 983-9	2.9	13
89	Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. <i>Journal of Clinical Pharmacology</i> , <b>2003</b> , 43, 831-9	2.9	106
88	First do no harm: managing antihistamine impairment in patients with allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2003</b> , 111, S835-42	11.5	111
87	Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. <i>Clinical Therapeutics</i> , <b>2003</b> , 25, 1407-19	3.5	76
86	Effect of mibefradil on CYP3A4 in vivo. <i>Journal of Clinical Pharmacology</i> , <b>2003</b> , 43, 1091-100	2.9	24
85	Characterization of Etoricoxib, a Novel, Selective COX-2 Inhibitor. <i>Journal of Clinical Pharmacology</i> , <b>2003</b> , 43, 573-585	2.9	55
84	Pharmacokinetics of intramuscularly administered ertapenem. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2003</b> , 47, 1732-5	5.9	24
83	Functional and molecular characterization of beta-adrenoceptors in the internal anal sphincter. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2003</b> , 305, 615-24	4.7	19
82	Bacterial enterotoxins are associated with resistance to colon cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 2695-9	11.5	118
81	Characterization of Etoricoxib, a Novel, Selective COX-2 Inhibitor <b>2003</b> , 43, 573		3
80	Characterization of etoricoxib, a novel, selective COX-2 inhibitor. <i>Journal of Clinical Pharmacology</i> , <b>2003</b> , 43, 573-85	2.9	21
79	Soluble guanylate cyclase is allosterically inhibited by direct interaction with 2-substituted adenine nucleotides. <i>FEBS Journal</i> , <b>2002</b> , 269, 2186-93		10

78	Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2002</b> , 46, 739-45	5.9	215
77	Pharmacokinetics of ertapenem in healthy young volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2002</b> , 46, 3506-11	5.9	118
76	Nitric oxide activation of soluble guanylyl cyclase reveals high and low affinity sites that mediate allosteric inhibition by calcium. <i>Biochemistry</i> , <b>2002</b> , 41, 3396-404	3.2	19
75	A comparative molecular field analysis (COMFA) of the structural determinants of heat-stable enterotoxins mediating activation of guanylyl cyclase C. <i>Journal of Medicinal Chemistry</i> , <b>2002</b> , 45, 1731-4	8.3	8
74	Does potency predict clinical efficacy? Illustration through an antihistamine model. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2002</b> , 89, 7-11; quiz 11-2, 77	3.2	19
73	In vivo imaging of human colon cancer xenografts in immunodeficient mice using a guanylyl cyclase C-specific ligand. <i>Journal of Nuclear Medicine</i> , <b>2002</b> , 43, 392-9	8.9	37
72	Ectopic expression of guanylyl cyclase C in adenocarcinomas of the esophagus and stomach. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2002</b> , 11, 739-44	4	17
71	Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2001</b> , 98, 7846-51	11.5	133
70	Manufacturer's drug interaction and postmarketing adverse event data: what are appropriate uses?. <i>Drug Safety</i> , <b>2001</b> , 24, 637-43	5.1	8
69	Nucleotide requirements for CDX2 binding to the cis promoter element mediating intestine-specific expression of guanylyl cyclase C. <i>FEBS Letters</i> , <b>2001</b> , 507, 128-32	3.8	11
68	Ectopic expression of guanylyl cyclase C in CD34+ progenitor cells in peripheral blood. <i>Journal of Clinical Oncology</i> , <b>2001</b> , 19, 3951-9	2.2	52
67	Cyclic Nucleotides and Protein Phosphorylation in Vascular Smooth Muscle Relaxation <b>2001</b> , 805-828		
66	Pharmacokinetics and safety of single intravenous infusions of the adenosine agonist, AMP 579, in patients with end-stage renal insufficiency. <i>Journal of Clinical Pharmacology</i> , <b>2000</b> , 40, 745-51	2.9	5
65	Human cholecystokinin-A receptor is not an oncofetal protein. <i>Digestive Diseases and Sciences</i> , <b>2000</b> , 45, 538-43	4	6
64	A splice variant of the transcript for guanylyl cyclase C is expressed in human colon and colorectal cancer cells. <i>Digestive Diseases and Sciences</i> , <b>2000</b> , 45, 298-305	4	4
63	Colorectal cancer staging and adjuvant chemotherapy. <i>Expert Opinion on Pharmacotherapy</i> , <b>2000</b> , 1, 737-55	4.5	15
62	Intestine-specific activity of the human guanylyl cyclase C promoter is regulated by Cdx2. <i>Gastroenterology</i> , <b>2000</b> , 119, 89-96	13.3	64
61	The guanylyl cyclase family of natriuretic peptide receptors. <i>Vitamins and Hormones</i> , <b>1999</b> , 57, 123-51	2.5	26

60	Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer. <i>Annals of Internal Medicine</i> , <b>1999</b> , 131, 805-12	8	84
59	Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. <i>Clinical Pharmacology and Therapeutics</i> , <b>1999</b> , 65, 348-52	6.1	57
58	The Molecular Therapeutics Section of the American Society for Clinical Pharmacology and Therapeutics. <i>Clinical Pharmacology and Therapeutics</i> , <b>1999</b> , 66, 336-7	6.1	2
57	Regulation of nitric oxide-responsive recombinant soluble guanylyl cyclase by calcium. <i>Biochemistry</i> , <b>1999</b> , 38, 6441-8	3.2	36
56	Interruption of transmembrane signaling as a novel antisecretory strategy to treat enterotoxigenic diarrhea. <i>FASEB Journal</i> , <b>1999</b> , 13, 913-22	0.9	20
55	Binding characteristics of <i>Ustilago maydis</i> topoisomerase I to DNA containing secondary structures. <i>FEBS Journal</i> , <b>1998</b> , 255, 347-55		7
54	Use of guanylyl cyclase C for detecting micrometastases in lymph nodes of patients with colon cancer. <i>Diseases of the Colon and Rectum</i> , <b>1998</b> , 41, 310-5	3.1	67
53	Paradoxical hypotension and bradycardia after intravenous arginine vasopressin. <i>Journal of Clinical Pharmacology</i> , <b>1998</b> , 38, 283-6	2.9	4
52	Adverse Drug Reactions: A Review. <i>Drug Information Journal</i> , <b>1998</b> , 32, 323-338		5
51	Effect of multiple doses of rifampin on the [ <sup>14</sup> C N-methyl] erythromycin breath test in healthy male volunteers. <i>Journal of Clinical Pharmacology</i> , <b>1998</b> , 38, 492-5	2.9	28
50	Single-dose pharmacokinetics of indinavir and the effect of food. <i>Antimicrobial Agents and Chemotherapy</i> , <b>1998</b> , 42, 332-8	5.9	99
49	Interruption of <i>Escherichia coli</i> heat-stable enterotoxin-induced guanylyl cyclase signaling and associated chloride current in human intestinal cells by 2-chloroadenosine. <i>Journal of Biological Chemistry</i> , <b>1997</b> , 272, 754-8	5.4	16
48	Cytoplasmic domains mediate the ligand-induced affinity shift of guanylyl cyclase C. <i>Biochemistry</i> , <b>1997</b> , 36, 12921-9	3.2	28
47	An intracellular adenine nucleotide binding site inhibits guanylyl cyclase C by a guanine nucleotide-dependent mechanism. <i>Biochemistry</i> , <b>1996</b> , 35, 3213-21	3.2	17
46	Hypotensive mechanisms of amifostine. <i>Journal of Clinical Pharmacology</i> , <b>1996</b> , 36, 365-73	2.9	25
45	Pharmacokinetics and pharmacodynamics of tepoxalin after single oral dose administration to healthy volunteers. <i>Journal of Clinical Pharmacology</i> , <b>1996</b> , 36, 462-8	2.9	21
44	Guanylyl cyclase C is a selective marker for metastatic colorectal tumors in human extraintestinal tissues. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1996</b> , 93, 14827-32	11.5	168
43	<i>Escherichia coli</i> heat-stable enterotoxin receptors. A novel marker for colorectal tumors. <i>Diseases of the Colon and Rectum</i> , <b>1996</b> , 39, 171-81	3.1	50



42	Inhibition of nitric oxide biosynthesis promotes P-selectin expression in platelets. Role of protein kinase C. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>1995</b> , 15, 2068-75	9.4	82
41	Rat guanylyl cyclase C expressed in COS-7 cells exhibits multiple affinities for Escherichia coli heat-stable enterotoxin. <i>Biochemistry</i> , <b>1995</b> , 34, 9095-102	3.2	16
40	Allosteric regulation by calcium of rabbit polyclonal anti-cyclic GMP antibody. <i>Biochimica Et Biophysica Acta - General Subjects</i> , <b>1995</b> , 1243, 143-50	4	2
39	Effects of food on the bioequivalence of different verapamil sustained-release formulations. <i>Journal of Clinical Pharmacology</i> , <b>1995</b> , 35, 163-9	2.9	18
38	Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin. <i>Journal of Clinical Pharmacology</i> , <b>1995</b> , 35, 1008-15	2.9	26
37	Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients. <i>Hypertension</i> , <b>1995</b> , 25, 37-46	8.5	96
36	Intestinal kinetics and dynamics of Escherichia coli heat-stable enterotoxin in suckling mice. <i>Journal of Infectious Diseases</i> , <b>1994</b> , 170, 1498-507	7	5
35	Escherichia coli heat-stable toxin receptors in human colonic tumors. <i>Gastroenterology</i> , <b>1994</b> , 107, 1653-61	6.3	78
34	Regulation of particulate guanylate cyclase by natriuretic peptides and Escherichia coli heat-stable enterotoxin. <i>Advances in Pharmacology</i> , <b>1994</b> , 26, 67-86	5.7	9
33	A 56 kDa binding protein for Escherichia coli heat-stable enterotoxin isolated from the cytoskeleton of rat intestinal membrane does not possess guanylate cyclase activity. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , <b>1993</b> , 1152, 1-8	3.8	12
32	Solubilization and characterization of functionally coupled Escherichia coli heat-stable toxin receptors and particulate guanylate cyclase associated with the cytoskeleton compartment of intestinal membranes. <i>International Journal of Biochemistry &amp; Cell Biology</i> , <b>1993</b> , 25, 557-66		18
31	Sensitivity in detecting drug-induced alterations in the PR interval: comparison of the surface electrocardiogram measured by a cardiologist versus routine automated computer analysis. <i>American Journal of Cardiology</i> , <b>1993</b> , 72, 834-6	3	7
30	Affinity purification of functional receptors for Escherichia coli heat-stable enterotoxin from rat intestine. <i>Biochemistry</i> , <b>1992</b> , 31, 12-6	3.2	48
29	Immunoaffinity purification of soluble guanylyl cyclase. <i>Methods in Enzymology</i> , <b>1991</b> , 195, 391-6	1.7	4
28	Copurification of atrial natriuretic peptide receptor and particulate guanylyl cyclase. <i>Methods in Enzymology</i> , <b>1991</b> , 195, 397-404	1.7	1
27	Identification of atrial natriuretic peptide receptors in cultured cells. <i>Methods in Enzymology</i> , <b>1991</b> , 195, 436-46	1.7	4
26	Adenine nucleotide regulation of particulate guanylate cyclase from rat lung. <i>BBA - Proteins and Proteomics</i> , <b>1991</b> , 1077, 99-106		31
25	Identification and characterization of a new family of high-affinity receptors for Escherichia coli heat-stable enterotoxin in rat intestinal membranes. <i>Biochemistry</i> , <b>1991</b> , 30, 10738-45	3.2	39



24	Rat intestinal cell atrial natriuretic peptide receptor coupled to guanylate cyclase. <i>Gastroenterology</i> , <b>1990</b> , 99, 125-31	13.3	15
23	Regulation of particulate guanylate cyclase by atriopeptins: relation between peptide structure, receptor binding, and enzyme kinetics. <i>BBA - Proteins and Proteomics</i> , <b>1989</b> , 999, 157-62		5
22	Regulation of particulate guanylate cyclase by Escherichia coli heat-stable enterotoxin: receptor binding and enzyme kinetics. <i>International Journal of Biochemistry &amp; Cell Biology</i> , <b>1989</b> , 21, 1211-5		5
21	Atrial natriuretic peptides: receptors and second messengers. <i>BioEssays</i> , <b>1989</b> , 10, 16-9	4.1	25
20	Comparison of particulate guanylate cyclase in cells with and without atrial natriuretic peptide receptor binding activity. <i>Molecular and Cellular Biochemistry</i> , <b>1989</b> , 90, 19-25	4.2	3
19	Cyclic Nucleotides and Protein Phosphorylation in Vascular Smooth-Muscle Relaxation. <i>Developments in Cardiovascular Medicine</i> , <b>1989</b> , 825-846		4
18	Atrial natriuretic peptide, oxytocin, and vasopressin increase guanosine 3'Smonophosphate in LLC-PK1 kidney epithelial cells. <i>Endocrinology</i> , <b>1988</b> , 122, 1478-85	4.8	26
17	Biochemical Mechanisms Underlying Vascular Smooth Muscle Relaxation. <i>Journal of Cardiovascular Pharmacology</i> , <b>1988</b> , 12, 115-118	3.1	94
16	Effect of in vivo nitroglycerin therapy on endothelium-dependent and independent vascular relaxation and cyclic GMP accumulation in rat aorta. <i>Journal of Cardiovascular Pharmacology</i> , <b>1987</b> , 10, 371-8	3.1	115
15	Regulation of guanylate cyclase by atrial natriuretic factor and the role of cyclic GMP in vasodilation. <i>American Journal of the Medical Sciences</i> , <b>1987</b> , 294, 139-43	2.2	34
14	Effects of glyceryl trinitrate on endothelium-dependent and -independent relaxation and cyclic GMP levels in rat aorta and human coronary artery. <i>Journal of Cardiovascular Pharmacology</i> , <b>1987</b> , 10, 82-9	3.1	84
13	Atrial natriuretic factors stimulate accumulation and efflux of cyclic GMP in C6-2B rat glioma and PC12 rat pheochromocytoma cell cultures. <i>Journal of Neurochemistry</i> , <b>1987</b> , 48, 522-8	6	55
12	Regulation of cyclic GMP synthesis and the interactions with calcium. <i>Journal of Cardiovascular Pharmacology</i> , <b>1986</b> , 8 Suppl 8, S57-60	3.1	11
11	The involvement of catalytic site thiol groups in the activation of soluble guanylate cyclase by sodium nitroprusside. <i>Archives of Biochemistry and Biophysics</i> , <b>1986</b> , 251, 709-14	4.1	39
10	Desensitization to nitroglycerin in vascular smooth muscle from rat and human. <i>Biochemical Pharmacology</i> , <b>1986</b> , 35, 3525-31	6	144
9	Effects of atriopeptins on relaxation and cyclic GMP levels in human coronary artery in vitro. <i>European Journal of Pharmacology</i> , <b>1986</b> , 124, 193-6	5.3	30
8	Effects of atriopeptins on relaxation and cyclic GMP levels in rat and rabbit aortas. <i>European Journal of Pharmacology</i> , <b>1986</b> , 120, 123-6	5.3	27
7	Atriopeptin II elevates cyclic GMP, activates cyclic GMP-dependent protein kinase and causes relaxation in rat thoracic aorta. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>1985</b> , 846, 179-84 <sup>4.9</sup>		91

6	Effects of atrial natriuretic factor, sodium nitroprusside, and acetylcholine on cyclic GMP levels and relaxation in rat aorta. <i>European Journal of Pharmacology</i> , <b>1985</b> , 115, 219-29	5.3	79
5	A common antigenic determinant found in two functionally unrelated toxins. <i>Journal of Experimental Medicine</i> , <b>1984</b> , 160, 1253-8	16.6	14
4	A simple, sensitive, and specific assay for the heat-stable enterotoxin of Escherichia coli. <i>Journal of Infectious Diseases</i> , <b>1984</b> , 149, 83-9	7	30
3	Atrial natriuretic factor elicits an endothelium-independent relaxation and activates particulate guanylate cyclase in vascular smooth muscle. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>1984</b> , 81, 7661-4	11.5	427
2	Highly purified particulate guanylate cyclase from rat lung: characterization and comparison with soluble guanylate cyclase. <i>Molecular and Cellular Biochemistry</i> , <b>1983</b> , 57, 155-66	4.2	23
1	Highly purified particulate guanylate cyclase from rat lung: characterization and comparison with soluble guanylate cyclase <b>1983</b> , 57, 155		1